Beyond BP Control: Optimizing Hypertension Management for Better Outcomes

Hypertension remains the leading modifiable risk factor for cardiovascular disease worldwide and is a major contributor to stroke, heart failure, chronic kidney disease, and premature mortality. Despite the availability of effective treatment options and established clinical guidelines, a substantial proportion of patients fail to achieve or maintain optimal blood pressure control in routine clinical practice. 

This speaker-led educational meeting will explore the evolving landscape of hypertension management, highlighting why achieving and sustaining blood pressure control is essential for improving cardiovascular outcomes. Participants will examine the challenges encountered in real-world clinical settings, including therapeutic inertia, poor adherence, delayed treatment intensification, and patient-related factors that contribute to suboptimal BP control. 

The session will review the rationale for early combination therapy and discuss key evidence from landmark studies, including the VALIANT and MARVAL studies, which have contributed to the understanding of cardiovascular and renal protection through optimal blood pressure management. Special emphasis will be placed on the role of RAAS-based combination therapy and how healthcare professionals can tailor treatment strategies to individual patient profiles. 

This speaker-led educational meeting will explore the importance of early and effective treatment intensification, with a focus on the rationale for combination therapy in patients with hypertension. Participants will review key evidence from landmark clinical studies, including the VALIANT and MARVAL studies, and examine their contribution to understanding cardiovascular and renal protection through effective blood pressure management.

Through evidence-based presentations and practical case discussions, healthcare professionals will gain insights into individualizing treatment decisions and selecting appropriate antihypertensive combinations to optimize treatment outcomes and translate evidence into every practice.

The programme combines concise talks, case-based application, a high-level discussion, and extended Q&A sessions.

TOPICS TO BE PRESENTED

1. The Evolving Landscape of Hypertension Management
2. Challenges in Achieving BP Control in Real-World Practice
3. Rationale for Early Combination Therapy
4. Choosing the Right Combination for the Right Patient

WHY YOU SHOULD ATTEND

· Gain clinical Insights from the VALIANT Study and MARVAL Study

· Understand the Role of RAAS-Based Combination Therapy

· Apply Knowledge through Interactive and Practical Clinical Case Discussions

PROUDLY SPONSORED BY

This is a virtual event scheduled for Thursday the 10th of September, 2026 at 16:00 GMT.  

Target Audience: Doctors and Pharmacists

Date: Thursday, 10th September, 2026 

Time: 16:00 GMT (4:00 PM Local Time)

Moderator:

Don’t miss out on this exciting opportunity to elevate your skills and make a lasting impact hypertension management!

PARTICIPANT CONSENT AND DATA PRIVACY NOTICE

By registering for the “Beyond BP Control: Optimizing Hypertension Management for Better Outcomes”, you consent to participate in this training hosted by Continuous Education Services (CES) on behalf of Novartis. Your registration will provide us with the necessary information to facilitate the event and issue CPD accreditation through the Medical and Dental Council (MDC) & Pharmacy Council (PC). CES is committed to safeguarding your personal information and will not share any personal data with Novartis. Your data will only be shared with the relevant regulatory bodies, such as MDC & PC, solely for accrediting CPD points earned through this training. Participants are free to opt out of the meeting at any time; no further action is required on your part. Your privacy is respected, and your participation will be treated with the highest level of confidentiality.